Protara Therapeutics, Inc.
TARA· Nasdaq
TARAProtara Therapeutics, Inc.
Filed Aug 11, 2026 · 10-Q · 42 days after period end · 0001213900-26-087508
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$21.67M | -$14.96M | -$9.51M | -$11.29M |
| EPS Diluted | -$0.36 | -$0.35 | -$0.45 | -$1.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end
